This bill amends section 1192(e) of the Social Security Act to change how the Drug Price Negotiation Program counts time since a drug’s approval. It directs the Secretary to exclude from the elapsed-time calculation any period during which a drug or biological product had orphan status under the statute, and it expands the statutory wording to cover drugs approved for one or more rare diseases using the FD&C Act definition.
The practical consequence is administrative: the statutory “clock” used to determine when a product becomes eligible for price negotiation will pause for periods of orphan designation, and drugs with multiple rare-disease indications are explicitly captured. That alters which products enter the negotiation pool and when — a change that matters to manufacturers, payers, and HHS implementation teams alike.
At a Glance
What It Does
The bill adds a rule that any time a drug or biologic spent as an orphan product must be ignored when calculating the elapsed time since approval for purposes of the Drug Price Negotiation Program. It also replaces language limiting orphan status to a single rare disease with wording that covers 'one or more' rare diseases and cross-references the FDA definition.
Who It Affects
Biopharmaceutical companies with products that received orphan designation at any point, manufacturers of biological products, and the HHS Secretary’s office that administers the negotiation program. Federal payers and insurers will see the downstream effects on which drugs become subject to negotiation and when.
Why It Matters
By pausing the negotiation clock during orphan-status periods and broadening the orphan-description language, the bill lengthens or preserves exclusionary status for treatments tied to rare-disease designations and removes ambiguity about multi-indication orphan products — shifting enrollment timing in the negotiation program and changing manufacturers' strategic calculus.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The ORPHAN Cures Act makes two targeted edits to the Drug Price Negotiation Program statute. First, it tells HHS not to count any span of time during which a drug or biologic was designated an orphan product when calculating how much time has elapsed since the product’s approval for purposes of determining negotiation eligibility.
In plain terms, if a medicine spent several years on the market while carrying orphan status, those years do not advance the statutory clock that eventually can make the product subject to federal price negotiation.
Second, the bill removes limiting language that treated an orphan approval as applying to “only one” rare disease or condition and replaces it with wording that covers approvals for one or more rare diseases, explicitly tying the phrase to the FDA’s statutory definition of rare disease in section 526(a)(2) of the FD&C Act. That change clarifies that a product approved for multiple rare indications still counts as an orphan product under the negotiation statute.Together, these edits change eligibility mechanics without creating a new subsidy or altering FDA’s designation process.
Practically, manufacturers whose products obtained orphan designation at any point will see that those designation periods extend the time before the product becomes eligible for negotiation because the clock is paused during orphan status. At the administrative level, HHS must determine how to document and apply historical orphan periods, classify periods of orphan status for products with shifting indications, and coordinate records with FDA and sponsors to implement the statutory pause.
The Five Things You Need to Know
The bill inserts a new subparagraph (C) into section 1192(e)(1) directing the Secretary to exclude from the elapsed-time calculation any period during which the drug or biologic qualified as an orphan product under paragraph (3)(A).
It explicitly applies the clock pause to both drugs and licensed biological products by referencing the approval and licensure provisions in subparagraphs (A)(ii) and (B)(ii).
The text replaces the phrase 'only one rare disease or condition' with 'one or more rare diseases or conditions' and cross-references the FD&C Act’s section 526(a)(2) definition of rare disease.
The change preserves or lengthens exclusionary status for products that held orphan designation at any time, because those designation periods do not count toward the statutory time-to-negotiation calculation.
Implementation requires HHS to reconcile FDA orphan-designation records with the negotiation program’s eligibility clock and to decide how to treat partial or interrupted designation periods.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title: 'ORPHAN Cures Act'
Provides the act’s short title—Optimizing Research Progress Hope And New Cures Act—so statutory edits in the bill can be cited to that name. This is a conventional drafting provision that has no substantive effect on program operations.
Pause the negotiation clock for time spent as an orphan product
Adds a targeted instruction to the Secretary that when calculating elapsed time since a product’s approval or biologic licensure for the Drug Price Negotiation Program, any period during which the product qualified as an orphan drug under paragraph (3)(A) must be disregarded. Mechanically, the Secretary will subtract orphan-period days from the numerator of the elapsed-time calculation. That changes the timing of when products become eligible for negotiation without changing the statutory duration thresholds themselves.
Broaden and clarify the statutory orphan-product description
Revises the paragraph that identifies orphan products by replacing 'only one rare disease or condition' with 'one or more rare diseases or conditions' and adds an express cross-reference to the FD&C Act definition. That resolves ambiguity about multi-indication products and aligns the negotiation statute with FDA’s statutory standard for rare diseases, so a drug approved for multiple orphan indications cannot be excluded on a drafting-technicality.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Manufacturers of drugs or biologics that obtained orphan designation: The bill prevents orphan-period time from counting toward the negotiation-eligibility clock, effectively extending the period before negotiation can apply to those products.
- Biotech companies pursuing multiple rare-disease approvals: By clarifying that orphan status can cover 'one or more' rare conditions, sponsors seeking multiple orphan indications reduce legal uncertainty about whether their products qualify for the orphan exclusion.
- Sponsors of previously designated orphan products that lost designation later: The provision protects products that once had orphan status by preserving those years from the elapsed-time calculation, which benefits companies with shifting indications or post-approval labeling changes.
Who Bears the Cost
- Federal payers, including Medicare: Fewer products or later entry into the negotiation pool can reduce the program’s ability to negotiate prices for certain medicines, potentially increasing federal drug spending compared with a tighter eligibility regime.
- Private and employer-sponsored plans and their beneficiaries: If negotiation is delayed for drugs with orphan designation, downstream price effects can spill over to commercial payers and out-of-pocket costs for patients.
- HHS (Office administering negotiation) and FDA coordination teams: Agencies must expand tracking, documentation, and interagency record-matching to implement the clock pause and to determine orphan-period start and end dates for each product.
Key Issues
The Core Tension
The central dilemma is between incentivizing development and access to treatments for rare diseases and empowering the Drug Price Negotiation Program to lower drug costs for payers; pausing the negotiation clock during orphan-status periods protects incentives for orphan R&D but simultaneously reduces the program’s reach and timing, forcing policymakers to trade off innovation encouragement against cost containment.
The bill solves a narrow ambiguity by pausing the negotiation clock during orphan-designation periods, but that simplicity masks implementation work and strategic incentives. HHS will need clear rules for identifying the start and end of 'orphan periods' and for handling cases where designation was applied, rescinded, or changed over time.
Historical recordkeeping between sponsors and FDA will be central; the statute does not specify burdens of proof or a documentation standard, leaving operational discretion to the Secretary.
The change also creates a measurable incentive for sponsors to seek or retain orphan designation, and it introduces a potential for gaming: companies might time submissions, maintain or withdraw designations, or pursue multiple orphan indications primarily to preserve exclusion from negotiation. Expanding the wording to 'one or more' rare diseases removes a drafting gap but also broadens the pool of products that can claim the pause, which could materially affect which drugs are negotiable.
The statute contains no guardrails (for example, limits on cumulative paused time or anti-abuse rules), so administrative policies and guidance will determine how large an effect these edits produce.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.